Patients with multiple myeloma treated with idecabtagene vicleucel, known as “ide-cel,” a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.
Epic Overdose Tales: Three LSD Trips that Flip the ‘Bad Trip’ Script | Psychedelic Spotlight
Psychedelic researchers have campaigned against the “good vs bad trip” concept for years. They theorize these potent compounds are complex “non-specific amplifiers”, broadly activating neural
October 25, 2023